Phase II clinical trials demonstrated that 9 patients (7%) with metastatic melanoma and 10 patients (7%) with metastatic renal cell cancer treated with biologic therapy of HD IL-2 achieved complete regression of disease with hypotension, secondary to underlying capillary leak, being the most commonly reported toxicity [7–9]. This evidence concerns the gene IL2 and metastatic melanoma.